DBV Technologies S.A. Stock News

DBV Technologies (NASDAQ:DBVT) had its price objective trimmed by HC Wainwright from $14.00 to $10.00 in a report released on Tuesday, Price Targets.com reports. The firm currently has a buy rating on the stock. Other equities research analysts also recently issued reports about the stock. Societe Generale upgraded shares of DBV Technologies from a hold []

DBV Technologies S.A. (NASDAQ:DBVT) traded at $1.63 at last check on Tuesday, December 21, made a downward move of -39.63% on its previous day’s price. Looking at the stock we see that its previous close was $2.70 and the beta (5Y monthly) reads 2.21 with the day’s price range being $2.66 – $2.74. In terms … How Are Things Looking For DBV Technologies S.A. (NASDAQ: DBVT) For The Short Term? Read More »

After reviewing the FDA''s information requests Full story available on Benzinga.com

The road ahead for the peanut allergy treatment Viaskin Peanut is going to be rockier than investors had hoped.

After reviewing the FDA's information requests and considering all other options, DBV Technologies (NASDAQ: DBVT) has decided not to pursue the sequential approach to develop Viaskin Peanut (aller

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2021 (Article 223-16 of the General Regulations of the Autorité des Marc

Zacks Investment Research lowered shares of DBV Technologies (NASDAQ:DBVT) from a buy rating to a hold rating in a report issued on Thursday morning, Zacks.com reports. According to Zacks, DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The []

DBV Technologies (NASDAQ:DBVT) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report issued on Friday, Zacks.com reports. The firm currently has a $3.25 price objective on the stock. Zacks Investment Researchs price target points to a potential upside of 19.49% from the stocks current price. According to []

DBV Technologies (NASDAQ:DBVT) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued to investors on Friday, Zacks.com reports. The brokerage presently has a $3.25 price objective on the stock. Zacks Investment Researchs price objective points to a potential upside of 19.49% from the companys previous []

Millennium Management LLC trimmed its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 23.5% during the second quarter, Holdings Channel.com reports. The institutional investor owned 778,042 shares of the companys stock after selling 238,897 shares during the quarter. Millennium Management LLCs holdings in DBV Technologies were worth $4,256,000 at the end of the most []

Montrouge, France, November 24, 2021 DBV Technologies to Participate in an Upcoming Investor Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical

Montrouge, France, November 24, 2021

DBV Technologies S.A. (DBVT) is technically in oversold territory now, so the heavy selling pressure might have exhausted.

DBV Technologies (NASDAQ:DBVT) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Tuesday, Zacks.com reports. The brokerage presently has a $3.50 price objective on the stock. Zacks Investment Researchs target price would indicate a potential upside of 13.64% from the companys previous close. []